|
Prescription Drug Search
Strengths available for Vigabatrin :
Strengths available for Vigabatrin sachet:
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about MyGlobalPharmacy.com
List of countries where we can ship Vigabatrin:
- Albania
- Anguilla
- Argentina
- Armenia
- Austria
- Barbados
- Belgium
- Bermuda
- Chile
- China
- Cuba
- Czech Republic
- Egypt
- Estonia
- Georgia
- Germany
- Greece
- Grenada
- Guadeloupe
- Guam
- Honduras
- Hungary
- India
- Italy
- Jordan
- Korea, South
- Latvia
- Lebanon
- Liechtenstein
- Malta
- Moldova, Republic of
- New Zealand
- Nicaragua
- Romania
- Saudi Arabia
- Singapore
- Switzerland
- Tonga
- United Kingdom, UK
- United States, US
Latest news releases on Vigabatrin:
Catalyst Pharmaceutical Partners Announces Completion of Enrollment in CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction - Yahoo Finance
CORAL GABLES, Fla., May 21, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX - News) today announced that patient enrollment in its CPP-109 vigabatrin Phase II(b) clinical trial has reached its goal of 200 cocaine ...
Catalyst Pharmaceutical Partners Reports Positive Results From Phase I(a) Clinical Study of CPP-115 - msnbc.com
CPP-115 is a novel GABA aminotransferase inhibitor and vigabatrin analogue that, based on preclinical studies to-date, is greater than 100 times more potent than vigabatrin and may have reduced side effects (e.g., visual field defects ...
Catalyst Pharmaceutical Partners Announces First Quarter 2012 Financial Results - Yahoo Finance
Catalyst has two products in development, and is currently evaluating its lead product candidate, CPP-109 (vigabatrin), for the treatment of cocaine dependency. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration ...
Catalyst Pharmaceutical Partners, Inc. : Catalyst Pharmaceutical Partners Announces First Quarter 2012 Financial Results - 4-traders (press release)
Catalyst has two products in development, and is currently evaluating its lead product candidate, CPP-109 (vigabatrin), for the treatment of cocaine dependency. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA ...
